Project: Advancing Antibody Drug Conjugates

Antibody drug conjugates (ADCs) are site-directed drugs with great potential, but most ADCs have uncontrollable drug-antibody-ratios (DARs). In Advanco we will demonstrate how ChromaCon’s MCSGP purification technology, in combination with Alphalyse’s analytical methods, can ensure narrow DAR profiles, thereby improving safety and efficacy of ADCs. To take the DAR control even further, ChromaCon will develop a novel linker technology with controllable linker attachment sites to the antibody.

Acronym	Advanco (Reference Number: 9503)
Duration	01/04/2015 - 01/04/2017
Project Topic	Other Industrial Technologies
Network	Eurostars 2
Call	Eurostars Cut-Off 2

Project partner

Number	Name	Role	Country
20874	ChromaCon AG	Coordinator	Switzerland
20875	Alphalyse A/S	Partner	Denmark